Investors
Information Disclosure
-
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT2024.04.29
-
VOLUNTARY ANNOUNCEMENT - 52 RESEARCH RESULTS WILL BE PRESENTED AT 2024 ASCO ANNUAL MEETING2024.04.29
-
VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG “TQA3038 (siRNA)” COMPLETED PHASE I CLINICAL STUDY2024.04.25
-
NEXT DAY DISCLOSURE RETURN2024.04.19
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.04.19
-
VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "ROVADICITINIB (TQ05105)" OBTAINED POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION2024.04.18
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.04.17
-
NEXT DAY DISCLOSURE RETURN2024.04.16